Abstract
Objective
The selection criteria for secondary cytoreductive surgery (SCS) for recurrent endometrial cancer (EC) remain to be defined. The present study aimed to identify predictors for favorable survival after SCS for the disease.
Methods
We retrospectively reviewed the medical records of 112 patients who relapsed by 2016 among 1052 who were diagnosed with primary EC between 1985 and 2014. Characteristics associated with overall survival (OS) after SCS were identified using univariate and multivariate analyses.
Results
Twenty-nine of the 112 patients who relapsed underwent SCS. Complete resection was achieved in 18 (62%) patients, whose OS after SCS was significantly better than that of patients receiving incomplete resection (68 vs. 20 months; p = 0.001). Endometrioid histology and performance status (PS) 0 were significant and independent factors for a favorable OS (p = 0.005, and 0.049). The OS of patients with both factors was better than patients with one or no factors (median 75, 19 and 4 months; p = 0.001 and 0.00001). The number of predictors was associated with the rate of complete resection (p = 0.001).
Conclusions
Patients with endometrioid histology and PS 0 should be offered SCS for recurrent EC. Prospective trials are warranted to verify this proposal.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386
Fung-Kee-Fung M, Dodge J, Elit L et al (2006) Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 101(3):520–529
Morris M, Alvarez RD, Kinney WK et al (1996) Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 60(2):288–291
Barakat RR, Goldman NA, Patel DA et al (1999) Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 75(1):99–102
Scarabelli C, Campagnutta E, Giorda G et al (1998) Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. Gynecol Oncol 70(1):90–93
Campagnutta E, Giorda G, Piero GD et al (2004) Surgical treatment of recurrent endometrial carcinoma. Cancer 100(1):89–96
Bristow RE, Santillan A, Zahurak ML et al (2006) Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol Oncol 103(1):281–287
Awtrey CS, Cadungog MG, Leitao MM et al (2006) Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol 102(3):480–488
Ren Y, Shan B, Shi D et al (2014) Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective study. BMC Cancer 14(1):135
Papadia A, Bellati F, Ditto A et al (2015) Surgical treatment of recurrent endometrial cancer: time for a paradigm shift. Ann Surg Oncol 22(13):4204–4210
Turan T, Tasci T, Karalok A et al (2015) Salvage cytoreductive surgery for recurrent endometrial cancer. Int J Gynecol Cancer 25(9):1623–1632
Bricou A, Bendifallah S, Daix-Moreux M et al (2018) A proposal for a classification for recurrent endometrial cancer: analysis of a French multicenter database from the FRANCOGYN Study Group. Int J Gynecol Cancer 28(7):1278–1284
Iwase H, Furukawa S, Hirasawa T et al (2018) The clinical features of recurrent endometrial cancer in Japan: chemotherapy instead of radiotherapy as postoperative adjuvant treatment. Int J Gynecol Cancer 28(8):1616–1623
Barlin JN, Puri I, Bristow RE (2010) Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 118(1):14–18
Gottwald L, Pluta P, Piekarski J et al (2010) Long-term survival of endometrioid endometrial cancer patients. Arch Med sci 6(6):937–944
Odagiri T, Watari H, Hosaka M et al (2011) Multivariate survival analysis of the patients with recurrent endometrial cancer. J Gynecol Oncol 22(1):3–8
Zang RY, Li ZT, Tang J et al (2004) Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100(6):1152–1161
Harter P, Heitz F, du Bois A (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep 14(6):539–543
Minaguchi T, Satoh T, Matsumoto K et al (2016) Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers. Int J Clin Oncol 21(3):573–579
Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289–295
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Shikama, A., Minaguchi, T., Takao, W. et al. Predictors of favorable survival after secondary cytoreductive surgery for recurrent endometrial cancer. Int J Clin Oncol 24, 1256–1263 (2019). https://doi.org/10.1007/s10147-019-01469-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-019-01469-z